Correction to the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino

Jonathan C. P. McGlinchey, Hemanth Tummala, Douglas H. Lester

    Research output: Contribution to journalArticle

    1 Citation (Scopus)
    50 Downloads (Pure)

    Abstract

    The very common GNB3 c.825C>T polymorphism (rs5443), is present in approximately half of all human chromosomes. Significantly the presence of the GNB3 825T allele has been strongly associated, with predisposition to essential hypertension. Paradoxically the presence of the GNB3 825T allele, in exon 10, introduces a pathogenic alternative RNA splice site into the middle of exon 9. To attempt to correct this pathogenic aberrant splicing, we therefore bioinformatically designed, using a Gene Tools® algorithm, a GNB3 specific, antisense morpholino. It was hoped that this morpholino would behave in vitro as either a potential “ splice blocker and/or exon skipper, to both bind and inhibit/reduce the aberrant splicing of the GNB3, 825T allele. On transfecting a human lymphoblast cell line homozygous for the 825T allele, with this antisense morpholino, we encouragingly observed both a significant reduction (from ~58% to ~5%) in the production of the aberrant smaller GNB3 transcript, and a subsequent increase in the normal GNB3 transcript (from ~42% to ~95%). Our results demonstrate the potential use of a GNB3 specific antisense morpholino, as a pharmacogenetic therapy for essential hypertension.
    Original languageEnglish
    Pages (from-to)257-265
    Number of pages9
    JournalNucleic Acid Therapeutics
    Volume26
    Issue number4
    Early online date30 Mar 2016
    DOIs
    Publication statusPublished - 1 Aug 2016

    Fingerprint

    Morpholinos
    Alternative Splicing
    Alleles
    Exons
    RNA Splice Sites
    Pharmacogenetics
    Human Chromosomes
    Chromosomes
    Polymorphism
    Genes
    Cells
    Cell Line
    Essential Hypertension
    Therapeutics

    Cite this

    McGlinchey, Jonathan C. P. ; Tummala, Hemanth ; Lester, Douglas H. / Correction to the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino. In: Nucleic Acid Therapeutics. 2016 ; Vol. 26, No. 4. pp. 257-265.
    @article{1ebb61a6f8aa46d4a26ed648679c37fe,
    title = "Correction to the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino",
    abstract = "The very common GNB3 c.825C>T polymorphism (rs5443), is present in approximately half of all human chromosomes. Significantly the presence of the GNB3 825T allele has been strongly associated, with predisposition to essential hypertension. Paradoxically the presence of the GNB3 825T allele, in exon 10, introduces a pathogenic alternative RNA splice site into the middle of exon 9. To attempt to correct this pathogenic aberrant splicing, we therefore bioinformatically designed, using a Gene Tools{\circledR} algorithm, a GNB3 specific, antisense morpholino. It was hoped that this morpholino would behave in vitro as either a potential “ splice blocker and/or exon skipper, to both bind and inhibit/reduce the aberrant splicing of the GNB3, 825T allele. On transfecting a human lymphoblast cell line homozygous for the 825T allele, with this antisense morpholino, we encouragingly observed both a significant reduction (from ~58{\%} to ~5{\%}) in the production of the aberrant smaller GNB3 transcript, and a subsequent increase in the normal GNB3 transcript (from ~42{\%} to ~95{\%}). Our results demonstrate the potential use of a GNB3 specific antisense morpholino, as a pharmacogenetic therapy for essential hypertension.",
    author = "McGlinchey, {Jonathan C. P.} and Hemanth Tummala and Lester, {Douglas H.}",
    year = "2016",
    month = "8",
    day = "1",
    doi = "10.1089/nat.2015.0571",
    language = "English",
    volume = "26",
    pages = "257--265",
    journal = "Nucleic Acid Therapeutics",
    issn = "2159-3337",
    publisher = "Mary Ann Liebert Inc.",
    number = "4",

    }

    Correction to the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino. / McGlinchey, Jonathan C. P.; Tummala, Hemanth; Lester, Douglas H.

    In: Nucleic Acid Therapeutics, Vol. 26, No. 4, 01.08.2016, p. 257-265.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Correction to the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino

    AU - McGlinchey, Jonathan C. P.

    AU - Tummala, Hemanth

    AU - Lester, Douglas H.

    PY - 2016/8/1

    Y1 - 2016/8/1

    N2 - The very common GNB3 c.825C>T polymorphism (rs5443), is present in approximately half of all human chromosomes. Significantly the presence of the GNB3 825T allele has been strongly associated, with predisposition to essential hypertension. Paradoxically the presence of the GNB3 825T allele, in exon 10, introduces a pathogenic alternative RNA splice site into the middle of exon 9. To attempt to correct this pathogenic aberrant splicing, we therefore bioinformatically designed, using a Gene Tools® algorithm, a GNB3 specific, antisense morpholino. It was hoped that this morpholino would behave in vitro as either a potential “ splice blocker and/or exon skipper, to both bind and inhibit/reduce the aberrant splicing of the GNB3, 825T allele. On transfecting a human lymphoblast cell line homozygous for the 825T allele, with this antisense morpholino, we encouragingly observed both a significant reduction (from ~58% to ~5%) in the production of the aberrant smaller GNB3 transcript, and a subsequent increase in the normal GNB3 transcript (from ~42% to ~95%). Our results demonstrate the potential use of a GNB3 specific antisense morpholino, as a pharmacogenetic therapy for essential hypertension.

    AB - The very common GNB3 c.825C>T polymorphism (rs5443), is present in approximately half of all human chromosomes. Significantly the presence of the GNB3 825T allele has been strongly associated, with predisposition to essential hypertension. Paradoxically the presence of the GNB3 825T allele, in exon 10, introduces a pathogenic alternative RNA splice site into the middle of exon 9. To attempt to correct this pathogenic aberrant splicing, we therefore bioinformatically designed, using a Gene Tools® algorithm, a GNB3 specific, antisense morpholino. It was hoped that this morpholino would behave in vitro as either a potential “ splice blocker and/or exon skipper, to both bind and inhibit/reduce the aberrant splicing of the GNB3, 825T allele. On transfecting a human lymphoblast cell line homozygous for the 825T allele, with this antisense morpholino, we encouragingly observed both a significant reduction (from ~58% to ~5%) in the production of the aberrant smaller GNB3 transcript, and a subsequent increase in the normal GNB3 transcript (from ~42% to ~95%). Our results demonstrate the potential use of a GNB3 specific antisense morpholino, as a pharmacogenetic therapy for essential hypertension.

    U2 - 10.1089/nat.2015.0571

    DO - 10.1089/nat.2015.0571

    M3 - Article

    VL - 26

    SP - 257

    EP - 265

    JO - Nucleic Acid Therapeutics

    JF - Nucleic Acid Therapeutics

    SN - 2159-3337

    IS - 4

    ER -